Matthias Schwab - Selected Publications#
Reustle A, Menig LS, Leuthold P, Hofmann U, Stühler V, Schmees C, Becker M, Haag M, Klumpp V, Winter S, Büttner FA, Rausch S, Hennenlotter J, Fend F, Scharpf M, Stenzl A, Bedke J, Schwab M*, Schaeffeler E*. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. Clin Transl Med 12(6):e883. 2022. (*contributed equally)
Jaeger SU, Wohlrab M, Schoene D, Chambers M, Tremmel R, Leocani L, Corriol-Rohou S, Klenk J, Sharrack B, Garcia-Aymerich J, Rochester L, Maetzler W, Puhan M, Schwab M*, Becker C*. Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving? Age Ageing 55:1-10, 2022 (*contributed equally)
Stanulla M, Schaeffeler E, Möricke A, Buchmann S, Zimmermann M, Igel S, Corbacioglu S, Niemeyer CM, Hartmann H, Illsinger S, Sauerbrey A, Junk SV, Schütte P, Hinze L, Lauten M, Modlich S, Kolb R, Rössig C, Schwabe G, Gneckow A, Fleischhack G, Schlegel PG, Schünemann HJ, Kratz C, Cario G, Schrappe M, Schwab M. Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. Leukemia, 35: 2650–2657, 2021
van Tilburg C, Pfaff E, Pajtler K, Langenberg K, Fiesel P, Jones B, Balasubramanian GP, Stark S, Johann P, Blattner-Johnson M, Schramm K, Dikow N, Hirsch S, Sutter C, Grund K, von Stackelberg A, Kulozik A, Lissat A, Borkhardt A, Meisel R, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, von Schweinitz D, Schmid I, Kramm C, von Bueren A, Calaminus G, Vorwerk P, Graf N, Westermann F, Fischer M, Eggert A, Burkhardt B, Wößmann W, Nathrath M, Hecker-Nolting S, Frühwald M, Schneider D, Brecht I, Ketteler P, Fulda S, Koscielniak E, Meister M, Scheer M, Hettmer S, Schwab M, Tremmel R, Øra I, Hutter C, Gerber N, Lohi O, Kazanowska B, Kattamis A, Filippidou M, Goemans B, Zwaan CM, Milde T, Jäger N, Wolf S, Reuss D, Sahm F, von Deimling A, Dirksen U, Freitag A, Witt R, Lichter P, Kopp-Schneider A, Jones D, Molenaar J, Capper D, Pfister S, Witt O. The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets. Cancer Discov 11: 2764–2779, 2021
Reustle A, Di Marco M, Meyerhoff C, Nelde A, Walz JS, Winter S, Kandabarau S, Büttner F, Haag M, Backert L, Kowalewski D, Rausch S, Hennenlotter J, Stühler V, Scharpf M, Fend F, Stenzl A, Rammensee HG, Bedke J, Stevanovic S, Schwab M*, Schaeffeler E*. Integrative –omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Med 2020,12(1):32 (*contributed equally)
Schroth W, Büttner F, Kandabarau S, Hoppe R, Fritz P, Kumbrink J, Kirchner T, Brauer HA, Ren Y, Henderson D, Madden S, Sauer G, Fehm T, Wallwiener D, Fasching P, Mürdter T, Schwab M for German Tamoxifen and AI Clinicians Group, Brauch H. Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients. Clin Cancer Res 26: 6523–6534, 202
Schaeffeler E, Jaeger SU, Klumpp V, Yang JJ, Igel S, Hinze L, Stanulla M, Schwab M. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genet Med. 2019; 21(9):2145-2150.
Brauch H, Schroth W, Mürdter T, Schwab M. Tamoxifen Pharmacogenetics and Metabolism: The Same Is Not the Same. J Clin Oncol 2019;37:1981-1982.
Bassler D, Shinwell ES, Hallman M, Jarreau PH, Plavka R, Carnielli V, Meisner C, Engel C, Koch A, Kreutzer K, van den Anker JN, Schwab M, Halliday HL, Poets CF; Neonatal European Study of Inhaled Steroids Trial Group. Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. N Engl J Med 378:148-57, 2018
Nishii R, Moriyama T, Janke L, Yang W, Suiter C, Lin TN, Li L, Kihira K, Toyoda H, Hofmann U, Schwab M, Takagi M, MorioT, Manabe A, Kham S, Jiang N, Rabin KR, Kato M, Koh K, Eng-Juh Yeoh A, Hori H, Yang JJ. Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and anti-leukemic efficacy. Blood 131: 2466-2474, 2018
Fujiwara R, Haag M, Schäffeler E, Nies AT, Zanger UM, Schwab M. Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. Hepatology 67:1609-1619, 2018
Amstutz U., Henricks L.M., Offer S.M., Barbarino J., Schellens J.H.M., Swen J.J., Klein T.E., McLeod H.L., Caudle K.E., Diasio R.B., Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin. Pharmacol. Ther. 103, 210-216, 2018
Winter S, Fisel P, Büttner F, Nies AT, Stenzl A, Bedke J, Schwab M*, Schäffeler E. Comment on „Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”. Sci Transl Med 9 (391), 2017 (* corresponding authors)
Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, Lin TN, Hoshitsuki K, Nersting J, Kihira K, Hofmann U, Komada Y, Kato M, McCorkle R, Li L, Koh K, Najera CR, Kham SK, Isobe T, Chen Z, Chiew EK, Bhojwani D, Jeffries C, Lu Y, Schwab M, Inaba H, Pui CH, Relling MV, Manabe A, Hori H, Schmiegelow K, Yeoh AE, Evans WE, Yang JJ. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 2016, 48:367-73
